Stay updated on Biomarker-Directed Combo for Advanced Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Biomarker-Directed Combo for Advanced Lung Cancer Clinical Trial page.

Latest updates to the Biomarker-Directed Combo for Advanced Lung Cancer Clinical Trial page
- Check2 days agoChange DetectedThe site software was updated from version 3.6.2 to 3.6.3. This change reflects a platform update with general improvements and bug fixes, without altering the study details shown on the page.SummaryDifference0.0%

- Check9 days agoChange DetectedRevision updated from v3.6.0 to v3.6.2, indicating an update to the page's underlying platform or CMS. This may include minor fixes or changes behind the scenes.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedRecruitment status is updated to indicate the study is no longer enrolling, and results have been posted. The page adds or updates navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and clarifies the Pembrolizumab-based intervention arms, including removal of outdated entries.SummaryDifference5%

- Check31 days agoChange DetectedThe page's revision label updated to v3.5.5, replacing the prior v3.5.4 to reflect a newer version of the page metadata.SummaryDifference0.0%

- Check52 days agoChange DetectedResults Submitted is now shown, replacing the previous No Results Posted, and the page revision has been updated to v3.5.4, removing the earlier v3.5.3 reference.SummaryDifference0.1%

- Check74 days agoChange DetectedClinicalTrials.gov page revision identifier updated from **v3.5.2** to **v3.5.3**, reflecting a site/system version change rather than a change to the underlying trial information.SummaryDifference0.0%

Stay in the know with updates to Biomarker-Directed Combo for Advanced Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Biomarker-Directed Combo for Advanced Lung Cancer Clinical Trial page.